ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ANGO vs MDXG // EV/EBITDA & P/E VALUATION

AngioDynamics Inc. (NASDAQ) VS. MiMedx Group Inc (NASDAQ) • 15-METRIC TALLY: ANGO 1 — MDXG 9
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANGO VS. MDXG) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ANGO MDXG SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 54.60% 82.60% -28.00 MDXG /gross-margins <GO>
Return on Invested Capital (ROIC) -23.40% 47.20% -70.60 MDXG /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 6.7x — TIE /valuation <GO>
Free Cash Flow Yield 0.10% 12.77% -12.67 MDXG /fcf-yield <GO>
Operating Margin -12.50% 15.30% -27.80 MDXG /operating-margins <GO>
Net Profit Margin -11.50% 11.60% -23.10 MDXG /net-margins <GO>
Revenue Growth (YoY) 9.50% 20.00% -10.50 MDXG /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 2.12 6.45 -4.33 MDXG /balance-sheet <GO>
Piotroski F-Score Quality 6/9 9/9 -3.00 MDXG /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 39.4 32.9 +6.54 ANGO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 10.0x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $519.4M $579.3M -$60.0M MDXG /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ANGO REV MDXG REV ANGO GROSS % MDXG GROSS % ANGO FCF MDXG FCF
FY 2025 $320.2M $418.6M 54.6% 82.6% $508.0K $74.0M
FY 2024 $292.5M $348.9M 53.9% 82.8% -$14.6M $66.2M
FY 2023 $303.9M $321.5M — — -$28.2M $26.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANGO // BETA —
MDXG // BETA —